Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $17.1 million.

  • ARS Pharmaceuticals' Gains from Investment Securities rose 1270.35% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 1270.35%. This contributed to the annual value of $15.2 million for FY2024, which is 3191.11% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Gains from Investment Securities stood at $17.1 million, which was up 1270.35% from $300000.0 recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Gains from Investment Securities ranged from a high of $17.1 million in Q3 2025 and a low of -$1.1 million during Q3 2022
  • In the last 5 years, ARS Pharmaceuticals' Gains from Investment Securities had a median value of $7.2 million in 2021 and averaged $7.4 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Gains from Investment Securities crashed by 11695.79% in 2022, and later soared by 146260.37% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $100000.0 in 2021, then plummeted by 1194.0% to -$1.1 million in 2022, then surged by 154.84% to $600000.0 in 2023, then skyrocketed by 1433.33% to $9.2 million in 2024, then soared by 85.94% to $17.1 million in 2025.
  • Its Gains from Investment Securities stands at $17.1 million for Q3 2025, versus $300000.0 for Q2 2025 and $1.3 million for Q1 2025.